tradingkey.logo

Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer

ReutersMar 4, 2025 3:31 PM

Shares of drug developer Acelyrin SLRN.O fall 12.7% to $2.30

SLRN reiterates its planned merger with Alumis, says unsolicited buyout offer from Concentra Biosciences is not expected to result in superior proposal

Concentra last month offered to buy Acelyrin for about $300 million, according to Reuters calculations

SLRN early in February agreed to merge with Alumis in all-stock transaction

Transaction is expected to close by Q2 2025

SLRN stock has fallen 67.3% in past 12 months

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI